Antineoplastic Agents, 1. Nonhormonal
This is not the most recent version, view other versions
This version
Antineoplastic Agents, 1. Nonhormonal
Abstract
This article contains sections titled:
1. |
Introduction |
2. |
Alkylating Agents |
2.1. |
Nitrogen Mustard Analogues |
2.2. |
Alkyl Sulfonates |
2.3. |
Ethylene Imines (Aziridines) |
2.4. |
Nitrosoureas |
2.5. |
Other Alkylating Agents |
3. |
Antimetabolites |
3.1. |
Folic Acid Analogues (Folate Antagonists) |
3.2. |
Purine Analogues |
3.3. |
Pyrimidine Analogues |
4. |
Vinca Alkaloids and Derivatives |
5. |
Podophyllotoxin Derivatives |
6. |
Taxanes |
7. |
Other Natural Products and Derivatives |
8. |
Anthracyclines and Related Substances |
9. |
Other Cytotoxic Antibiotics |
10. |
Platinum Compounds |
11. |
Methylhydrazines |
12. |
Sensitizers for Photodynamic Therapy |
13. |
Protein Kinase Inhibitors |
14. |
Other Antineoplastic Agents |
References
- 1 P. Boyle, B. Levin (eds.), WHO World Cancer Report 2008, International Agency for Research on Cancer (IARC), Lyon 2008.
- 2 National Cancer Institute, USA, http://www.cancer.gov/cancertopics (accessed Nov. 2009).
- 3
H. zur Hausen,
Angew. Chem.
121
(2009)
5910.
10.1002/ange.200901917 Google Scholar
- 4 S. Missailidis (ed.): The Cancer Clock, chap. 9, John Wiley & Sons, New York 2007.
- 5 J.G. Hardman, L.E. Limbird, A.G. Gilman: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill, New York 2001.
- 6 S. Sweetman (ed.): Martindale: The Complete Drug Reference, 35th ed., Pharmaceutical Press, London 2007, pp. 586–591.
- 7 The Pharmaceutical Research and Manufacturers of America, Medicines in Development for Cancer, 2009 report, http://www.phrma.org (accessed Nov. 2009).
- 8 A. Kamb et al.: “Why is cancer drug discovery so difficult?”, Nature Rev. Drug Discovery 6 (2007) 115.
- 9 World Health Organisation, classifications, http://www.who.int/classifications/atcddd/ (accessed Nov. 2009).
- 10 Index Nominum, International Drug Directory, 19th ed., pharmaSuisse, MedPharm, Bern/CH, 2008.
- 11 Chem. Eng. News 86 (2008) no. 24, 17–27.
- 12 A. Gilman, F.S. Philips, Science 103 (1946) 409.
- 13 W. Sneader: Drug Discovery–A History, John Wiley & Sons, Chichester 2005, p. 440.
- 14 H. Arnold, F. Bourseaux, Angew. Chem. 70 (1958) 539.
- 15 H. Arnold et al.: “Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester”, Nature 181 (1958) 931.
- 16 N. Brock: “Zur pharmakologischen Charakterisierung zyklischer N-Lost-Phosphamidester als Krebs-Chemotherapeutika”, Arzneim.-Forsch./Drug Res. 8 (1961) 1.
- 17 Asta-Werke, US 3 018 302, 1962; DE-prior.1956.
- 18 Asta-Werke, DE 1 057 119; DE-prior.1956.
- 19 NRDC, US 2 944 079, 1960; GB-prior.1952.
- 20 Burroughs Wellcome, US 3 046 301, 1962; US-prior.1959.
- 21 J.L. Everett, J. Chem. Soc. 1953, 2390.
- 22 NRDC, US 3 032 584, 1962; GB-prior. 1953.
- 23 NRDC, US 3 032 585, 1962; GB-prior. 1954.
- 24 F. Bergel, J.A. Stock, J. Chem. Soc. 1954, 2409; 1955, 1223.
- 25 W.E. Hanby, H.N. Rydon, J. Chem. Soc. 1947, 513.
- 26 V. Prelog, V. Stepan, Coll. Czech. Chem. Commun. 7 (1935) 93.
- 27 Asta-Werke, DE 1 645 921; DE-prior.1966.
- 28 Asta-Werke, US 3 732 340, 1973; US-prior. 1967, 1970.
- 29 Asta-Werke, US 4 220 660, 1980; DE-prior. 1977 (comb.w/Mesna).
- 30 ASTA Medica, US 4 882 452, 1989; DE-prior. 1988.
- 31 ASTA Medica, US 5 696 172, 9.12.1997; DE-prior. 8.10.1992.
- 32 ASTA Medica, US 6 187 941, 13.2.2001; DE-prior. 6.9.1997.
- 33 AB Leo, US 3 732 260, 1973; GB-prior. 1969.
- 34 W. Ozegowski, D. Krebs, J. Prakt. Chem. 20 (1963) 178.
- 35 Wellcome Found., GB 700 677, GB-prior. 1950.
- 36 Burroughs Wellcome, US 2 917 432, 1959.
- 37 J.S. Sandberg et al., Cancer Chemother. Rep. Part 2, 30 (1972) 137.
- 38 American Cyanamid, US 2 670 347, 1954; US-prior. 1952.
- 39 American Cyanamid, US 4 918 199, 1990; US-prior. 1988.
- 40 Bayer AG, US 2 976 279, 1961; DE-prior. 1957.
- 41 W. Baker, J. Chem. Soc. 1941, 665.
- 42 Sankyo, US 3 631 026, 1971; JP-prior. 1968.
- 43 T.P. Johnston et al., J. Med. Chem. 6 (1963) 669.
- 44 T.P. Johnston et al., J. Med. Chem. 9 (1966) 892.
- 45 T.P. Johnston et al., J. Med. Chem. 18 (1975) 104.
- 46 T.P. Johnston et al., J. Med. Chem. 14 (1971) 600.
- 47 R.R. Herr et al., Antibiot. Annu. 1959-60, 230.
- 48 R.R. Herr et al., J. Amer. Chem. Soc. 89 (1967) 4808.
- 49 Upjohn, US 3 027 300, 1962; US-prior. 1958.
- 50 Upjohn, US 3 577 406, 1971; US-prior. 1968.
- 51 ADIR, US 4 567 169. 1986; FR-prior. 1982.
- 52 Sankyo, US 4 003 901, 1977; JP-prior. 1971.
- 53 Tokyo Tanabe, US 4 057 684, 1977; JP-prior. 1975.
- 54 Tokyo Tanabe, US 4 156 777, 1979; JP-prior. 1977.
- 55 Chinoin, GB 959 407, 1964; H-prior. 1961.
- 56 Abbott Labs., DE 1 138 781, 1963; US-prior. 1960.
- 57 S. Groszkowski et al., J. Med. Chem. 11 (1968) 621.
- 58 Cancer Res. Campaign Technokogy Ltd., US 5 260 291, 1993; GB-prior.1981.
- 59 M.F.G. Stevens et al., J. Med. Chem. 27 (1984) 196.
- 60 Y. Wang et al., J. Org. Chem. 27 (1997) 2150.
- 61 Schering Corp., US 7 087 751, 2006; US-prior. 2001.
- 62 J.F. Shealy et al., J. Org. Chem. 27 (1962) 2150.
- 63 D. Seeger et al., J. Am. Chem. Soc. 71 (1949) 1753.
- 64 C.W. Waller et al., J. Am. Chem. Soc. 70 (1948) 19.
- 65 American Cyanamid, US 2 512 572, 1950; US-prior.1947.
- 66 J.R. Piper, J.A. Montgomery, US 4 079 056, 1978; US-prior.1975.
- 67 P.R. Marsham et al., J. Med. Chem. 34 (1991) 1594.
- 68 ICI Pharmaceuticals, US 4 992 550, 1991; GB-prior.1986.
- 69 E.C. Taylor et al., J. Med. Chem. 35 (1992) 4450.
- 70 Trustees of Princeton University, US 5 344 932, 1994; US-prior. 1989.
- 71 Takeda, US 5 106 974, 21.04.1992; JP-prior. 24.03.1988.
- 72 D.P. Kjell et al., Org. Process Res. Dev. 3 (1999) 184.
- 73 Eli Lilly, EP 905 128, 20.02.2002; US-prior. 26.09.1997.
- 74 E.C. Taylor, B. Liu, J. Org. Chem. 68 (2003) 9938.
- 75 G.B. Elion et al., J. Am. Chem. Soc. 74 (1952) 411.
- 76 Burroughs Wellcome, US 2 697 709, 1954; GB-prior. 1951.
- 77 Burroughs Wellcome, US 2 721 866, 1955; US-prior. 1954.
- 78 Burroughs Wellcome, US 2 724 711, 1955; US-prior. 1954.
- 79 G.H. Hitchings and G.B. Elion, US 2884 667, 1959; US-prior. 1955.
- 80 Burroughs Wellcome, US 3 132 144, 1964; US-prior. 1959.
- 81 Brigham Young University, US 4 760 137, 26.07.1988, US-prior. 6.8.1984, 15.01.1987.
- 82 Z. Kazimerczuk et al., J. Amer. Chem. Soc. 106 (1984) 6379.
- 83 Ortho Pharmaceutical, US 5 208 327, 04.05.1993; US-prior. 18.12.1991, 16.04.1992.
- 84 Brigham Young University, US appl. 2007/0032645 A1, 08.02.2007; US-prior. 04.10.2002, 25.09.2002.
- 85 USA, Dept.of Health, Education & Welfare, US 4210745, 1980; US-prior. 1978.
- 86 USA, Dept.of Health, Education & Welfare, US 4 357 324, 1982; US-prior. 1981.
- 87 Schering AG, US 5 602 246, 11.02.1997; US-prior. 25.11.1992.
- 88 W.E. Bauta et al., Org.Process Res. & Dev. 2004, 8, 889.
- 89 Ilex Products, US 6 680 382, 20.01.2004; US-prior. 02.08.2001, 01.08.2002.
- 90 Sloan-Kettering Inst. Cancer Res., US 4 751 221, 1988; US-prior. 1985.
- 91 Sloan-Kettering Inst. Cancer Res., US 4 918 179, 17.04.1990; US-prior. 1985, 1988.
- 92 Southern Res. Inst., US 6 949 640, 27.09.2005; US-prior. 18.02.2000, 16.02.2001.
- 93 Burroughs Wellcome, US 5 424 295, 13.06.1995; GB-prior. 30.05.1987.
- 94 Upjohn, US 3 116 282, 1963; US-prior. 1959.
- 95 T.Y. Shen et al., J. Org. Chem. 30 (1965) 835.
- 96 Roche, US 2 802 005, 1957; US-prior. 1956.
- 97 R. Duschinsky, J. Amer. Chem. Soc. 79 (1957) 4559.
- 98 D.H.R. Barton et al., J. Org. Chem. 37 (1972) 329.
- 99 I.L. Knuniants et al., US 3 682 917, 1972; US-prior. 1970.
- 100 S.A. Giller et al., US 3 846 429, 1974; US-prior. 1971.
- 101 S.A. Giller et al., US 3 635 946, 1972; US-prior. 1967, 1969.
- 102 S.A. Giller et al., US 3 912 734, 1975; USSR-prior. 1972.
- 103 S.A. Giller et al., US 4 039 546, 1977; US-prior. 1975.
- 104 Asahi Kasei, US 4 107 162, 1978; JP-prior. 1975.
- 105 Mitsui, US 4 071 519, 1978; US-prior.1975.
- 106 L.W. Hertel et al., J. Org. Chem. 53 (1988) 2406.
- 107 Eli Lilly, US 4 526 988, 1985; US-prior. 1983.
- 108 Eli Lilly, US 4 965 374, 23.10.1990; US-prior. 28,08.1987,24.08.1988, 4.12.1989.
- 109 Eli Lilly, US 5 223 608, 29.06.1993; US-prior. 28.08.1987, 24.08.1988, 4.12.1989, 12.07.1990.
- 110 Eli Lilly, US 5 637 688, 10.06.1997; US-prior. 13.12.1994.
- 111 Eli Lilly, US 5 808 048, 15.09.1998; US-prior. 13.12.1994, 11.04.1997.
- 112 Roche, US 4 071 680, 1978; US-prior. 1976.
- 113 Syntex Corp., US 3 687 931, 1972; US-prior. 1970.
- 114 Roche, US 5 472 949, 05.12.1995; EU-prior. 18.12.1992.
- 115 Roche, US 5 476 932, 19.12.1995; US-prior. 26.08.1994.
- 116 A.F. Cook et al., J. Med. Chem. 22 (1979) 1330.
- 117 H. Aoyama, Bull. Chem. Soc. Jpn., 1987, 60, 2073.
- 118 Roche, US 2 885 396, 1959; US-prior. 1957.
- 119 Roche, US 2 949 451, 1960; US-prior. 1959.
- 120 Canadian Patents and Development, Ottawa, US 3 097 137, 1963; US-prior. 02.12.1958, 19.05.1960.
- 121 R.L. Noble et al., Ann. N.Y. Acad. Sci. 76 (1958) 882.
- 122 N. Neuss et al., J. Amer. Chem. Soc. 81 (1959) 4754.
- 123 Eli Lilly, US 3 225 030, 1965; US-prior. 25.08.1958, 1, 08.07.1960, 07.08.1961.
- 124 Richter Gedeon, US 4 070 358, 1978; H-prior. 1975.
- 125 Eli Lilly, US 3 205 220, 1965; US-prior. 1961.
- 126 Richter Gedeon, US 3 899 493, 1975; US-prior. 1972.
- 127 Eli Lilly, US 4 203 898, 1980; US-prior. 1973, 1974, 1975, 1976, 1977, 1978.
- 128 Eli Lilly, US 4 479 957, 1984; US-prior. 1973, 1974, 1975, 1976, 1977, 1978, 1979, 1981.
- 129 ANVAR, US 4 307 100, 1981; FR-prior. 1978, 1979.
- 130 P. Mangeney et al., J. Org. Chem. 44 (1979) 3765.
- 131 Eli Lilly, US 4 029 663, 1977, US-prior. 1975.
- 132 S. Raucher et al., J. Amer. Chem. Soc. 109 (1987) 442.
- 133 Mitsui, EP 354 778, 16.03.1994; JP-prior. 11.08.1988.
- 134 Sandoz, US 3 524 844, 1970; CH-prior. 1965, 1966.
- 135 C. Keller-Juslen et al., J. Med. Chem. 14 (1971) 936.
- 136 Shanghai Institute of Pharmaceut. Industry, US 5 206 350, 27.04.1993; CH-prior. 07.06.1990.
- 137 P. Allevi et al., J. Org. Chem. 58 (1993) 4175.
- 138 L.J. Silverberg et al., Org. Lett. 2 (2000) 3281.
- 139 M.C. Wani et al., J. Am. Chem. Soc. 93 (1971) 2325.
- 140 M.E. Wall, in D. Lednicer (ed.): Chronicles of Drug Discovery, vol. 3, Washington 1993, p. 340.
- 141 P.B. Schiff et al., Nature 277 (1979) 665.
- 142 R.A. Holton et al., J. Am. Chem. Soc. 116 (1994) 1597.
- 143 K.C. Nicolaou et al.. Nature 367 (1994) 630.
- 144 K.C. Nicolaou et al., Angew. Chem. Int. Ed. Engl. 33 (1994) 15.
- 145 Rhone-Poulenc Sante, US 4 814 470, 21.03.1989; FR-prior. 17.07.1986.
- 146 Florida State Univ., US 5 015 744, 14.05.1991 (R.A. Holton); US-prior. 14.11.1989.
- 147 Florida State Univ., US 5 136 060, 04.08.1992 (R.A. Holton); US-prior. 14.11.1989, 30.10.1990.
- 148 Florida State Univ., US 5 254 703, 19.10.1993 (R.A. Holton); US-prior. 06.04.1992.
- 149 A.K. Singh et al. (BMS), Org. Proc. Res. Dev. 7 (2003) 25.
- 150 F. Guéritte-Voegelein et al., J. Med. Chem. 34 (1991) 992.
- 151 Rhone-Poulenc Sante, US 4 814 470, 21.03.1989; FR-prior. 17.07.1986.
- 152 Rhone-Poulenc Sante, US 4 924 012, 08.05.1990; FR-prior. 06.04.1988.
- 153 Phyton, US 5 407 816, 18.04.1995, US-prior. 20.02.1992.
- 154 Phyton, US 7 264 951, 04.09.2007, US-prior. 20.02.1992.
- 155www.phytonbiotech.com.
- 156 Board of Trustees of the University of Illinois, US 5 089 273, 1992; US-prior. 09.06.1986, 21.08.1986, 23.01.1987, 01.06.1987, 01.12.1988, 05.07.1990.
- 157 PharmaMar, US 7 202 361, 10.04.2007; GB-prior. 12.04.2000.
- 158 C. Cuevas et al. (PharmaMar), Org. Lett. 2 (2000) 2545.
- 159 E.J. Corey et al., J. Am. Chem. Soc. 118 (1996) 9202.
- 160 G. Höfle et al., Angew.Chem. Int. Ed. Engl. 35 (1996) 1567.
- 161 GBF, DE 4 138 042, 14.10.1993; DE-prior. 19.11.1991.
- 162
K.C. Nicolaou et al.,
Angew. Chem.
110
(1998)
2120.
10.1002/(SICI)1521-3757(19980803)110:15<2120::AID-ANGE2120>3.0.CO;2-5 Google Scholar
- 163 Bristol-Myers Squibb, US 6 605 599, 12.08.2003; US-prior. 08.07.1997
- 164 Merck & Co., US 2 378 876, 1945; US-prior. 1941.
- 165 A. Di Marco et al., Nature 201 (1964) 706.
- 166 F. Arcamone et al., J. Amer. Chem. Soc. 86 (1964) 5334.
- 167 F. Arcamone in J.S. Bindra and D. Lednicer (eds.): Chronicles of Drug Discovery, Wiley, New-York 1983, p. 171.
- 168 Farmitalia, US 4 012 284, 1977; IT-prior. 16.11.1962.
- 169 Rhone-Poulenc, US 3 997 662, 1976; FR-prior. 18.05.1962.
- 170 Rhone-Pouienc, US 3 997 663, 1976; FR-prior. 18.05.1962.
- 171 Rhone-Poulenc, US 3 997 661, 1976; FR-prior. 15.11.1967.
- 172 Sanraku-Ocean, US 4 592 999, 1986; JP-prior. 24.07.1982.
- 173 Pharmacia & Upjohn, US 5 989 869, 23.11.1999; USA-prior. 06.03.1997.
- 174 Farmitalia, US 3 590 028, 1971; IT-prior. 1967.
- 175 Pharmacia & Upjohn, US 6 210 930,03.04.2001; USA-prior. 06.03.1997.
- 176 Farmitalia, US 3 803 124, 1974; IT-prior. 1968.
- 177 Sicor, US 5 945 518, 31.08.1999; IT-prior. 22.05.1995.
- 178 Farmitalia, US 4 058 519, 1977; GB-prior. 1974.
- 179 F. Arcamone et al., J. Med. Chem. 18 (1975) 703.
- 180 Pharmachemie B.V., US 5 874 550, 23.02.1999; EU-prior. 16.12.1996.
- 181 Sidney Farber Cancer Institute, US 4 035 566, 1977; US-prior.1975.
- 182 I.C. Cotterill, J.O. Rich, Org. Proc. Res. & Dev. 9 (2005) 818.
- 183 Rhone-Poulenc, DE 2 327 211, 1977; DE-prior. 1973.
- 184 C.M. Wong et al., Can. J. Chem. 49 (1971) 2712.
- 185 Farmitalia, US 4 046 878, 1977; GB-prior. 1974.
- 186 Farmitalia, US 5 103 029, 07.04.1992; GB-prior. 11.04.1988.
- 187 CM. Wong et al., Can. J. Chem. 49 (1971) 2712.
- 188 Adria Labs., US 4 471 052, 1984; US-prior. 1982.
- 189 T. Oki et al., J. Antibiot. 28 (1975) 830; 30 (1977) 683; 32 (1979) 801.
- 190 Institute of Microbial Chemistry Japan, US 3 988 315, 1976; JP-prior. 1974.
- 191 K.C. Murdock et al., J. Med. Chem. 22 (1979) 1024.
- 192 American Cyanamid, US 4 197 249, 1980; US-prior.1977.
- 193 American Cyanamid, US 4 278 689, 1981; US-prior.1977.
- 194 American Cyanamid, US 4 820 738, 1989; US-prior. 1977.
- 195 H. Umezawa et al., J. Antibiot. 19 (1966) 200, 210.
- 196 Institute of Microbial Chemistry, US 3 846 400, 1974; JP-prior. 1969.
- 197 Institute of Microbial Chemistry, US-Re. 30 451, 1980; JP-prior. 1969.
- 198 Grundy et al., Antibiot. Chemother. 3 (1953) 1215.
- 199 J. Thiem, B. Meyer, Tetrahedron 37 (1981) 551.
- 200 Kyowa Hakko, US 3 660 578, 1972; JP-prior. 1957.
- 201 Bristol-Myers, US 3 042 582, 1962; USA-prior. 1958.
- 202
M. Peyrone,
Ann. Chem. Pharm.
51
(1845)
no. 1,
1–29.
10.1002/jlac.18440510102 Google Scholar
- 203 A. Werner, Z. Anorg. Chem. 1893, 3, 267.
- 204 B. Rosenberg et al., Nature 205 (1965) 698.
- 205 B. Rosenberg et al., Nature 222 (1969) 385.
- 206 G.B. Kauffman, D.O. Cowan, Inorg. Synth. 7 (1963) 239.
- 207 J.W. Reishus et al., J. Am.Chem.Soc. 83 (1961) 2457.
- 208 S.C. Dhara, Indian J. Chem. 8 (1970) 193.
- 209 MPD Technol.Corp., US 4 273 755, 1981; US-prior.1979.
- 210 MPD Technol.Corp., US 4 335 087, 1982; US-prior.1979.
- 211 Research Corp. N.Y., US 4 140 707, 1979; US-prior.1972.
- 212 Nat. Cancer Center, Tokyo, US 4 169 846, 1979; JP-prior.1976
- 213 Y. Kidani, US 4 255 347, 1981; JP-prior. 1978
- 214 Tanaka, US 5 290 961, 01.03.1994; JP-prior.13.01.1992
- 215 Tanaka, US 5 420 319, 30.05.1995; JP-prior. 21.05.1993
- 216 Roche, US 3 520 926, 1970; CH-prior.1961.
- 217 K.E. Borbas, D. Lahaye, Photodynamic Therapy of Cancer in S. Missailidis (ed.), Anticancer Therapeutics, Wiley-Blackwell, Oxford 2008, pp. 187–222.
- 218 A. Jesionek, H. von Tappenier, Muench. Med. Wochenschrift 47 (1903) 204.
- 219 H. Ali, J.E. van Lier, Chem.Rev. 99 (1999) 2379–2450.
- 220 Health Research, Inc., US 4 649 151, 1987; US-prior. 1982.
- 221 E.D. Sternberg et al., Tetrahedron 54 (1998) 4151.
- 222 N.I. Aronova et al., US 3 846 490, 1974; appl. 1972.
- 223 Efamol Holdings PLC, US 4 992 257, 12.02.1991; GB-prior. 11.03.1988.
- 224 Univ. Of British Columbia, US 5 095 030, 10.03.1992; CAN-prior. 19.01.1988.
- 225 Center for Innovative Technol. Richmond, Va., US 5 049 695, 17.09.1991; USA-prior. 12.02.1990.
- 226 J.A. Bikker et al., J. Med. Chem. 52 (2009) 1493–1509.
- 227 A. Crespo et al., J. Med. Chem. 51 (2008) 4890–4898.
- 228 R. Airley: Tyrosine kinase inhibitors, Cancer Chemotherapy, chap. 14, Wiley-Blackwell, Oxford 2009, pp. 217–223.
- 229 P.A. Jänne et al., Nature Reviews Drug Discovery 8 (2009) 709–723.
- 230 J. Zimmermann et al., Bioorg. Med. Chem. Lett. 12 (1997) 187.
- 231 Ciba-Geigy, US 5 521184, 28.05.1996; CH-prior. 03.04.1992, 01.10.1993.
- 232 Y.-F. Liu et al., Org. Proc. Res. & Dev. 12 (2008) 490.
- 233 Zeneca, US 5 770 599, 23.06.1998; GB-prior. 27.04.1995.
- 234 Pfizer, US 5 747 498, 05.05.1998; USA-prior. 06.06.1995, 28.05.1996.
- 235 Sugen, US 5 792 783, 11.08.1998; USA-prior. 07.06.1995, 05.06.1996.
- 236 L Sun et al., J. Med. Chem. 46 (2003) 1116.
- 237 J.M. Manley et al., J. Org. Chem. 68 (2003) 6447.
- 238 Bayer, WO 0042012, 20.07.2000; US-prior. 13.01.1999, 25.02.1999, 22.10.1999.
- 239 D. Bankston et al., Org. Proc. Res. & Dev. 6 (2002) 777.
- 240 Bristol-Myers Squibb, US 6 596 746, 22.07.2003; US-prior. 15.04.1999,13.04.2000.
- 241 LJ. Lombardo et al., J. Med. Chem. 47 (2004) 6658.
- 242 SmithKline Beecham, US 7 109 333, 19.09.2006; GB-prior. 12.01.1998.
- 243 Novartis, WO 2004/005281, 15.01.2004; GB-prior. 05.07.2002.
- 244 B.F. Cain et al., J. Med. Chem. 18 (1975) 1110.
- 245 Cassella, US 3 424 752, 1969; DE-prior. 1965.
- 246 DuPont, US 2 705 727, 1955; US-prior.1952.
- 247 Parke Davis, US 3 923 785, 1975; US-prior. 1974.
- 248 Warner-Lambert, US 5 463 035, 31.10.1995; US-prior. 31.07.1991.
- 249 Max-Planck-Gesellschaft, US 4 837 023, 1989; DE-prior. 1985, 1986.
- 250 Max-Planck-Gesellschaft, US 5 049 552, 1991; DE-prior. 1985, 1986.
- 251 Max-Planck-Gesellschaft, EP 225 608, DE-prior. 1985.
- 252 ASTA Medica, EP 521 297, 1997; DE-prior.1991.
- 253 Leo AB, US Re. 29 199, 1977; GB-prior. 1963 (Reissue of US 3 299 104).
- 254 SmithKline Beecham, US 5 004 758, 02.04.1991; US-prior. 01.12.1987, 02.11.1988.
- 255 W.D. Kingsbury et al., J. Med. Chem. 34 (1991) 98.
- 256 Yakult Honsha, US 4 604 463, 1986; JP-prior. 1983.
- 257 S. Sawada et al., Chem. Pharm. Bull. 39 (1991) 1446.
- 258 B.L. Hailer et al., J. Am. Chem. Soc. 67 (1945) 1591.
- 259 M.F. Boehm et al., J. Med. Chem. 37 (1994) 2930.
- 260 Ligand Pharmaceuticals, WO 93/21146, publ. 28.10.1993; US-prior.22.04.1992.
- 261 Memorial Sloan-Kettering Cancer Center, US 6 723 351, 20.04.2004; US-prior. 10.11.1997.
- 262 W.H. Miller et al., Cancer Res. 62 (2002) 3893.
- 263 ProScript, Inc., US 5 780 454, 14.07.1998; USA-prior. 28.10.1994
- 264 J. Adams et al., Bioorg. Med. Chem. Lett. 8 (1998) 333.
- 265 Sloan-Kettering Inst. For Cancer Res., US 5 369 108, 29.11.1994; US-prior. 04.10.1991.
- 266 J.C. Stowell et al., J. Med. Chem. 38 (1995) 1411.
Further Reading
- R. Airley: Cancer Chemotherapy: Basic Science to the Clinic 1st ed, Wiley, New York, 2009.
- B. A Chabner, D. L. Longo: Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott Williams & Wilkins, Philadelphia 2010.
- E. Chu, V. T. DeVita: Physicians' Cancer Chemotherapy Drug Manual (Jones and Bartlett Series in Oncology, physician's Cancer Che) 10th ed., Jones & Bartlett Publishers, London 2009.
- Edward Chu: Pocket Guide to Hematologic Cancer Chemotherapy Protocols, Jones & Bartlett Publisher, London 2010.
- F. P. Miller, A. F. Vandome, J. McBrewster: Cancer Research: Basic research, Clinical trial, Surgery, Chemotherapy, Hormone therapy, Biotechnology, Cancer, Oncology, Epidemiology of cancer, Alternative cancer treatments, Alphascript Publishing, Mauritius 2010.
